Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Recent
Upcoming
Share :

ASH 2021

Videos
News
Real-world evidence on PET use in Hodgkin lymphoma: An Argentinian perspective
Dr Marta Zerga - Hospital Alemán , Buenos Aires, Argentina
Real-world evidence on PET use in Hodgkin lymphoma: An Argentinian perspective ( Dr Marta Zerga - Hospital Alemán , Buenos Aires, Argentina )
3 Mar 2022
Brentuximab vedotin and CHP benefit over CHOP for CD30-positive PTCL
Dr Juliana Pereira & Dr Steven Horwitz
Brentuximab vedotin and CHP benefit over CHOP for CD30-positive PTCL ( Dr Juliana Pereira & Dr Steven Horwitz )
22 Feb 2022
PET scanning in patients with classical Hodgkin lymphoma outside of Europe and...
Prof Mark Hertzberg - University of New South Wales, Sydney, Australia
PET scanning in patients with classical Hodgkin lymphoma outside of Europe and North America ( Prof Mark Hertzberg - University of New South Wales, Sydney, Australia )
22 Feb 2022
Frontline treatment with single agent pembrolizumab followed by AVD...
Prof Pamela Allen - Emory University School of Medicine, Georgia, USA
Frontline treatment with single agent pembrolizumab followed by AVD chemotherapy for classic Hodgkin lymphoma ( Prof Pamela Allen - Emory University School of Medicine, Georgia, USA )
22 Dec 2021
Efficacy and safety of selinexor in patients with myelofibrosis refractory or...
Prof Srinivas Tantravahi - University of Utah, Salt Lake City, USA
Efficacy and safety of selinexor in patients with myelofibrosis refractory or intolerant to JAK inhibitors ( Prof Srinivas Tantravahi - University of Utah, Salt Lake City, USA )
20 Dec 2021
Significance of gut microbiota in patients receiving CAR T cell immunotherapy
Prof Marco Ruella - University of Pennsylvania, Philadelphia, USA
Significance of gut microbiota in patients receiving CAR T cell immunotherapy ( Prof Marco Ruella - University of Pennsylvania, Philadelphia, USA )
17 Dec 2021
INTEGRATE study: Treatment pathways, outcomes and resource use in patients with...
Prof Meral Beksac and Prof Roman Hájek
INTEGRATE study: Treatment pathways, outcomes and resource use in patients with multiple myeloma ( Prof Meral Beksac and Prof Roman Hájek )
15 Dec 2021
Glow study: MRD outcomes after fixed-duration Ibr+Ven versus Clb+O for first...
Dr Arnon Kater - Amsterdam UMC, Amsterdam, Netherlands
Glow study: MRD outcomes after fixed-duration Ibr+Ven versus Clb+O for first-line treatment of CLL in elderly or unfit patients ( Dr Arnon Kater - Amsterdam UMC, Amsterdam, Netherlands )
14 Dec 2021
Tisagenlecleucel shows no EFS improvement on standard of care in 2L for...
Dr Michael Bishop - University of Chicago, Chicago, USA
Tisagenlecleucel shows no EFS improvement on standard of care in 2L for aggressive B-cell NHL ( Dr Michael Bishop - University of Chicago, Chicago, USA )
14 Dec 2021
Integrated genomic analysis identifies UBTF tandem duplications as a subtype...
Dr Masayuki Umeda - St. Jude Children's Research Hospital, San Francisco, USA
Integrated genomic analysis identifies UBTF tandem duplications as a subtype-defining lesion in paediatric AML ( Dr Masayuki Umeda - St. Jude Children's Research Hospital, San Francisco, USA )
14 Dec 2021
Asciminib found to be safe and effective for heavily pretreated patients with...
Dr Michael Mauro - Memorial Sloan Kettering Cancer Center, New York, USA
Asciminib found to be safe and effective for heavily pretreated patients with chronic myeloid leukaemia in chronic phase ( Dr Michael Mauro - Memorial Sloan Kettering Cancer Center, New York, USA )
14 Dec 2021
Long-term OS benefit with oral azacitidine for acute myeloid leukaemia in first...
Prof Andrew Wei - Monash University, Melbourne, Australia
Long-term OS benefit with oral azacitidine for acute myeloid leukaemia in first remission after intensive chemo ( Prof Andrew Wei - Monash University, Melbourne, Australia )
13 Dec 2021
Allogeneic haematopoietic cell transplantation in adults with Ph-like ALL
Dr Ibrahim Aldoss - City of Hope, Duarte, USA
Allogeneic haematopoietic cell transplantation in adults with Ph-like ALL ( Dr Ibrahim Aldoss - City of Hope, Duarte, USA )
13 Dec 2021
Azacitidine, venetoclax and gilteritinib for FLT3-mutated AML
Prof Nicholas Short - The University of Texas MD Anderson Cancer Center...
Azacitidine, venetoclax and gilteritinib for FLT3-mutated AML ( Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA )
13 Dec 2021
Ten-day decitabine with venetoclax in acute myeloid leukaemia: Updated outcomes...
Dr Abhishek Maiti - The University of Texas MD Anderson Cancer Center, Houston...
Ten-day decitabine with venetoclax in acute myeloid leukaemia: Updated outcomes across genomic subgroups ( Dr Abhishek Maiti - The University of Texas MD Anderson Cancer Center, Houston, USA )
13 Dec 2021
Axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory...
Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA
Axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory large B-cell lymphoma ( Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA )
13 Dec 2021
EURO-SKI: 46% of CML patients still in molecular recurrence- and treatment-free...
Prof Francois-Xavier Mahon - University of Bordeaux, Bordeaux, France
EURO-SKI: 46% of CML patients still in molecular recurrence- and treatment-free survival 3 years after TKIs ( Prof Francois-Xavier Mahon - University of Bordeaux, Bordeaux, France )
13 Dec 2021
Real world data supports ciltacabtagene autoleucel as effective option for...
Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca...
Real world data supports ciltacabtagene autoleucel as effective option for triple-class exposed r/r MM ( Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca, Spain )
12 Dec 2021
Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared...
Dr Martin Kaiser - The Institute of Cancer Research, London UK
Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared with myeloma XI/XI+ Trial treatment for Uhir MM ( Dr Martin Kaiser - The Institute of Cancer Research, London UK )
12 Dec 2021
Monoclonal antibody-based quadruplet therapy, AHCT and MRD response-adapted...
Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA
Monoclonal antibody-based quadruplet therapy, AHCT and MRD response-adapted consolidation therapy gives highest rate of MRD negativity in NDMM ( Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA )
12 Dec 2021
Latest in combination therapy for NDMM patients
Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA
Latest in combination therapy for NDMM patients ( Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA )
12 Dec 2021
Lenalidomide and rituximab as front-line chemo-free therapy for elderly frail...
Dr Guido Gini - Università Politecnica delle Marche, Ancona, Italy
Lenalidomide and rituximab as front-line chemo-free therapy for elderly frail patients with diffuse large B-cell lymphoma. ( Dr Guido Gini - Università Politecnica delle Marche, Ancona, Italy )
11 Dec 2021
Antibody and T-cell responses to COVID-19 vaccination in myeloproliferative...
Dr Chi-Joan How - Brigham and Women's Hospital, Boston, USA
Antibody and T-cell responses to COVID-19 vaccination in myeloproliferative neoplasm patients ( Dr Chi-Joan How - Brigham and Women's Hospital, Boston, USA )
11 Dec 2021
Allogeneic CAR-T PBCAR0191 with intensified lymphodepletion is highly active in...
Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA
Allogeneic CAR-T PBCAR0191 with intensified lymphodepletion is highly active in pts with relapsed/refractory B-cell malignancies ( Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )
11 Dec 2021
Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma
Prof Ryan Lynch - University of Washington School of Medicine, Seattle, USA
Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma ( Prof Ryan Lynch - University of Washington School of Medicine, Seattle, USA )
11 Dec 2021
ZUMA-12: A phase 2 study of axi-cel as first-line therapy in patients with high...
Prof Sattva Neelapu - The University of Texas MD Anderson Cancer Center...
ZUMA-12: A phase 2 study of axi-cel as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL) ( Prof Sattva Neelapu - The University of Texas MD Anderson Cancer Center, Houston, USA )
11 Dec 2021
Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL
Prof Brian Hill - Cleveland Clinic, Cleveland, USA
Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL ( Prof Brian Hill - Cleveland Clinic, Cleveland, USA )
11 Dec 2021
Mosunetuzumab induces deep and durable remissions in 3L R/R follicular lymphoma
Prof Elizabeth Budde - City of Hope, Duarte, USA
Mosunetuzumab induces deep and durable remissions in 3L R/R follicular lymphoma ( Prof Elizabeth Budde - City of Hope, Duarte, USA )
11 Dec 2021
Study indicates circulating tumour cell assessment should be part of multiple...
Dr Juan-José Garcés - Clinica Universidad de Navarra, Pamplona, Spain
Study indicates circulating tumour cell assessment should be part of multiple myeloma diagnostic workup ( Dr Juan-José Garcés - Clinica Universidad de Navarra, Pamplona, Spain )
11 Dec 2021
Initial treatment options for relapsed/refractory multiple myeloma patients
Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca...
Initial treatment options for relapsed/refractory multiple myeloma patients ( Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca, Spain )
11 Dec 2021
ZUMA-5 update: Axicabtagene ciloleucel continues to show strong effect in R/R...
Prof Sattva Neelapu - The University of Texas MD Anderson Cancer Center...
ZUMA-5 update: Axicabtagene ciloleucel continues to show strong effect in R/R iNHL ( Prof Sattva Neelapu - The University of Texas MD Anderson Cancer Center, Houston, USA )
11 Dec 2021
Lisocabtagene maraleucel demonstrates improvement over standard of care in 2L...
Dr Manali Kamdar - The University of Colorado Anschutz Medical Campus, Aurora...
Lisocabtagene maraleucel demonstrates improvement over standard of care in 2L LBCL ( Dr Manali Kamdar - The University of Colorado Anschutz Medical Campus, Aurora, USA )
11 Dec 2021

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation